What is he best known for?
The fields of study he is best known for:
- Gene
- Internal medicine
- Immune system
Tomas Olsson mainly focuses on Immunology, Multiple sclerosis, Internal medicine, Experimental autoimmune encephalomyelitis and Antibody.
Tomas Olsson combines subjects such as Myelin and Myelin basic protein with his study of Immunology.
His Multiple sclerosis research includes elements of Genetics, Neurology, Autoimmunity and Pathology.
His study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology and Surgery.
His work deals with themes such as T cell, Neuroinflammation and Calcium channel, which intersect with Experimental autoimmune encephalomyelitis.
In his research, Lymphocyte differentiation, Genetic architecture and Spleen is intimately related to Cellular immunity, which falls under the overarching field of Antibody.
His most cited work include:
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (1970 citations)
- Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. (797 citations)
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis (628 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Immunology, Multiple sclerosis, Internal medicine, Experimental autoimmune encephalomyelitis and Antibody.
His Immunology research is multidisciplinary, relying on both Myelin and Myelin basic protein.
His Multiple sclerosis research includes elements of Odds ratio, Cerebrospinal fluid, Pathology and Human leukocyte antigen.
His Internal medicine study which covers Teriflunomide that intersects with Adverse effect and Tolerability.
His work is dedicated to discovering how Experimental autoimmune encephalomyelitis, T cell are connected with Molecular biology and other disciplines.
He studied Antibody and Peripheral blood mononuclear cell that intersect with Cytokine.
He most often published in these fields:
- Immunology (50.22%)
- Multiple sclerosis (49.12%)
- Internal medicine (23.35%)
What were the highlights of his more recent work (between 2016-2021)?
- Multiple sclerosis (49.12%)
- Internal medicine (23.35%)
- Immunology (50.22%)
In recent papers he was focusing on the following fields of study:
Tomas Olsson mostly deals with Multiple sclerosis, Internal medicine, Immunology, Neurology and Human leukocyte antigen.
The Multiple sclerosis study combines topics in areas such as Odds ratio, Disease and Confidence interval.
The various areas that Tomas Olsson examines in his Internal medicine study include Neuropathic pain, Expanded Disability Status Scale and Oncology.
Immune system, Epstein–Barr virus, T cell, Experimental autoimmune encephalomyelitis and Myelin oligodendrocyte glycoprotein are subfields of Immunology in which his conducts study.
His T cell research is multidisciplinary, incorporating elements of Autoimmunity and Antigen.
He has included themes like MEDLINE, Young adult, Retrospective cohort study, Dementia and Pediatrics in his Neurology study.
Between 2016 and 2021, his most popular works were:
- Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. (156 citations)
- Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis (154 citations)
- Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis (154 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Internal medicine
- Immune system
Tomas Olsson spends much of his time researching Multiple sclerosis, Neurology, Internal medicine, Immunology and Oncology.
His study in Multiple sclerosis focuses on Fingolimod in particular.
Tomas Olsson interconnects MEDLINE, Young adult, Cognition, Dementia and Pediatrics in the investigation of issues within Neurology.
His research investigates the link between Internal medicine and topics such as Dimethyl fumarate that cross with problems in Alemtuzumab, Teriflunomide and Gene.
His Immunology study combines topics in areas such as Cerebrospinal fluid and Neurogranin.
His Oncology research is multidisciplinary, incorporating perspectives in Natalizumab and Expanded Disability Status Scale.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
